Logo

Novartis Collaborates with Artios Pharma to Discover Next Generation DDR Cancer Therapies

Share this
Novartis Collaborates with Artios Pharma to Discover Next Generation DDR Cancer Therapies

Novartis Collaborates with Artios Pharma to Discover Next Generation DDR Cancer Therapies

Shots:

  • Artios to receive $20M upfront in addition to near term research funding to support the collaboration and is eligible to receive $1.3B in discovery- development- regulatory- and sales milestones along with royalties on net sales of products
  • Novartis to utilize Artios’ discovery platform to discover and validate DDR targets to enhance its radioligand therapies- selects up to three exclusive DDR targets- and will additionally receive WW rights on these targets to be used with its RLT’s
  • The collaboration does not include Artios’ lead programs (ART0380 and ART4215)- currently under clinical development

  Ref: GlobeNewswire | Image: Novartis

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions